
CONTENTS

SECTION 1 HYPERTENSION

- 1. Pitfalls in Hypertension Management3**
K Tewary
Errors in Examination 3
Diagnostic Errors 3
Treatment Errors 4
Errors by Patients 4
- 2. Ambulatory Blood Pressure Monitoring in Clinical Practice.....6**
Narayan G Deogaonkar, Viplav N Deogaonkar
- 3. Azilsartan: A New Baby in Old Horizon 17**
BA Muruganathan
Evolution of the Angiotensin II Receptor Blockers 17
Angiotensin Receptor Blockers: Beyond Blood Pressure Lowering Effects 18
Tolerability 18
Direct AT1R Effects of Azilsartan 19
Azilsartan: Potent AT1 Receptor Binding 19
Azilsartan: Pleiotropic Effects Beyond BP Lowering 19
Azilsartan: Potential Effect in Cardio-Renal Protection 20
Summary of the Unique Features of Azilsartan 22
- 4. Hypertension and Menopause 24**
Anuj Maheshwari, Shipra Kunwar
Role of Oxidative Stress and Vasoconstrictors 24
Hypertension: The Key Risk Factor during Menopause 26
How should It be Treated? 27
- 5. Renovascular Hypertension: Current Status..... 28**
Puneet Rijhwani
Pathogenesis 28
Renovascular Hypertension: Major Causes 28
Diagnosis 29
Medical Management 30

Surgical Revascularization 31

Angioplasty 31

6. Diuretics for Hypertension: Review and Update..... 33

R Rajasekar

Effect of Low Dose Diuretic 33

Types of Diuretics 33

Potassium-Sparing Common Combination Diuretics 35

Combination of Diuretic with Anti-HT Drugs 35

7. High Altitude Systemic Hypertension: Unraveling the Mystery 36

VA Kothiwale, Deebanshu Gupta

Effects of High Altitude on Cardiovascular System 36

Need for Definition of HASH – and Its Prevalence 36

Pathophysiology of Hash 38

Role of Endothelin 1 40

Ageing, High Altitude and Blood Pressure-A Complex Relationship 41

Blood Pressure Changes with Aging 41

How BP Behaves with Aging in People Chronically Exposed to High Altitude 42

Importance of Recognizing Hash 42

Diagnosis of HASH 42

Treatment of HASH 42

8. Management of Isolated Systolic Hypertension: Current Concepts 44

Girish Mathur, Shrikant Chaudhary

Prevalence and Risk Factor 44

Classification of ISH 45

Evaluation of ISH 45

Management of Hypertension 45

Benefits of Treatment of ISH 48

Interventional Trial Concerning ISH 48

Smaller Studies on ISH 48

9. Blood Pressure Control with Changing Time 50

BR Bansode

Management of Hypertension 50

JNC 1974 to 2003 (1 to 7) 51

Conclusion and Perspectives 54

10. Management of Hypertension in Diabetes	55
BB Thakur, Smita Thakur	
Hypertension	55
Pharmacologic Treatment	58
Gestational Diabetes	61
11. Grey Areas in Diagnosis and Management of Hypertension	67
Anita Jaiswal	
Rule of Halves	67
Types of Blood Pressure Instruments	70

SECTION 2 CARDIOLOGY

12. Atherosclerosis: Can We Tame it?	75
Harendra Kumar	
Methods are Carotid Intima-Media Thickness (CIMT)	75
Cholesterol Absorption Inhibitor	77
13. Cardiac Cachexia	80
AKP Singh	
Pathophysiology	80
Anabolic Failure	80
Catabolic Activation	80
Insulin Resistance	80
Skeletal Muscle	81
14. Is Intervention Still Relevant in Stable CAD?	82
Santanu Guha, Bappaditya Kumar	
Management of Stable Coronary Artery Disease	82
Indications for PCI	83
Improvement in Survival with PCI	83
Relief of Angina	83
Patients without Clear Indications for Intervention	84
15. Newer Oral Anticoagulants in Clinical Practice	86
Anshul Kumar Jain	
Comparison of NOACs with VKA	86

16. Dual Antiplatelet Therapy: How Long?	90
Sameer Kumar, Girish MP, Mohit D Gupta	
What is the Debate? 90	
Risk Stratification 90	
Short-term versus Long Term DAPT: The Evidence So Far 91	
Duration of Dual Antiplatelet Therapy in Cases of Stable Coronary Artery Disease (CAD) After PCI 91	
Duration of Dual Antiplatelet Therapy in Patients Presenting with Acute Coronary Syndrome (ACS) 92	
Duration of DAPT in Patients Undergoing CABG 93	
Elective Noncardiac Surgery in Patients Treated with DAPT and PCI 93	
Switch Over Between Antiplatelets 94	
Special Circumstances 94	
17. Newer Biomarkers in Heart Failure	97
Saumitra Ray	
Diagnosis 97	
Other Biomarkers 98	
Biomarkers of HFpEF 98	
18. Coronary Microvascular Dysfunction: An Update	100
SM Mustafa Zaman	
Risk Factors and Pathophysiology 100	
Diagnosis 102	
Clinical Profile 102	
Treatment of Coronary Microvascular Dysfunction 104	
19. How did Fractional Flow Reserve Change My Clinical Decisions? Case-based Discussions	110
Nagendra Boopathy Senguttuvan	
Fractional Flow Reserve 110	
Characteristics of FFR 110	
Functional PCI 111	
Deferred PCI 112	
Assessment of Serial Lesions 112	
20. Mega Trials in Cardiology	115
Sundeep Mishra	
Hypertension Trials 115	
Secondary Prevention of CAD 116	
Hope Trial 116	
Arrhythmia 117	

Heart Failure	117
Diabetes Mellitus	118
21. Rheumatic Valvular Heart Disease	121
RR Singh	
Signs and Symptoms	121
Mitral Stenosis	122
Mitral Stenosis with Close-up on Mitral Valve	122
Medical Treatment	124
Surgical Treatment	124
22. Advances in Management of Pulmonary Arterial Hypertension.....	125
Abhishek Gupta, S Ramakrishnan	
Current Epidemiology	125
Management of PAH	125
Newly Approved Medications for PAH	126
Combination Therapy	127
Nonpharmacological Options	128
Stem Cell Therapy	128
Lung Transplantation	128
23. Infective Endocarditis: An Update	129
Sudhir Varma, Samman Verma, Rommel Singh	
Changing Epidemiological Profile	129
Diagnostic Issues	129
Antimicrobial Therapy	129
Complications	130
Indications for Surgery	131
Prevention	132
24. Pregnancy and Heart Disease	133
Gurleen Wander, Gurpreet Singh Wander	
Physiological Changes in Pregnancy	133
Peripartum Cardiomyopathy	134
Rheumatic Heart Disease	135
Prosthetic Heart Valves	135
Aortic Dissection	135
Congenital Heart Disease	136
General Principles of Management	136
Intrapartum	136

- 25. A Review of Cardiorenal Syndrome 138**
 Gurinder Mohan, Ranjeet Kaur, Aakash Aggarwal
 Pathophysiology 139
 Biomarkers in Cardiorenal Syndrome 140
 Management 141
- 26. Heart Failure with Reduced Ejection Fraction: Treatment Strategy 144**
 Amal Kumar Banerjee
 Classification 144
 Diagnosis 145
 Pharmacologic Treatment 147
 Nonsurgical Device Treatment 147
 Mechanical Circulatory Support and Heart Transplantation 148
 Heart Failure and Comorbidities 149
 Arrhythmias and Conductance Disturbances 149
 Monitoring 149
- 27. Pulmonary Embolism: Focus on New Drugs 151**
 VK Katyal, Ashima Katyal, Naman Mukhi
 Pathophysiology 151
 Clinical Presentations 151
 Diagnosis 152
 Management of Acute Pulmonary Embolism 153
- 28. Echocardiographic Navigation of AF from Irregular Pulse to Slurring of the Speech:
 Relevant at All Stages in India and the Real World 157**
 HK Chopra, Ravi R Kasliwal, Manish Bansal, Shraddha Ranjan
 Echocardiographic Navigation in AF Management 158

SECTION 3 DIABETES

- 29. ADA Standards of Care: An Update 173**
 Abhishek Pandey
 Section Changes 173
 Staging of Type 1 Diabetes 174
 Pharmacologic Therapy for Diabetes 175
- 30. Can Medical Care Change the Natural History of T2DM: Turning Fiction into Reality? 181**
 Rajesh Rajput

31. Are all Gliptins the Same: How to Decide and Choose?	186
Harbir Kaur Rao, Rajinder Singh Gupta	
Pathogenesis of Type 2 Diabetes Mellitus	186
Ideal Antihyperglycemic Drug	187
Dipeptidyl Peptidase-4 Inhibitors	187
Efficacy	188
Safety	189
32. Diabetes and Inflammation	191
Jugal Kishor Sharma, Girish Khurana	
Link Between Diabetes and Inflammation	191
Clinical Implications of Inflammation in Type-2 Diabetes	195
Clinical Benefits Based on Inflammatory Theory	195
Drugs Related to the Endoplasmic Reticulum Stress Theory	195
33. Pollution and Diabetes: Is there a Link?	198
Brij Mohan	
Persistent Organic Pollutants	198
Air Pollutants Sources	200
34. Musculoskeletal Manifestations of Diabetes Mellitus.....	203
S Anita Nambiar, Divya G	
Limited Joint Mobility/ Rosenbloom Syndrome	203
Adhesive Capsulitis of the Shoulder	204
Dupuytren's Contracture/Disease	204
Hyperostosis	204
Carpal Tunnel Syndrome	204
Flexor Tenosynovitis	205
Neuroarthropathy (Charcot's Joints)	205
Diabetic Amyotrophy	205
Osteoporosis	205
Diabetic Muscle Infarction	205
Reflex Sympathetic Dystrophy	206
35. How to Hold the HOLD?	207
NK Singh, Vaibhav Agnihotri, Richa Singh Agnihotri	
Prevalence	207
Peculiarities of HOLD in India	207
Mechanistic Characteristics	208

- Behavioral Modification 208
- Physical Activity 209
- Getting Rid of Persistent Organic Pollutants 209
- Pharmacological Interventions 210
- 36. Dyslipidemia Management: Newer Avenues.....211**
Nirupam Prakash
CETP Inhibitors 214
- 37. Metformin versus Insulin in Treatment of Gestational Diabetes Mellitus.....217**
Sandeep Garg, Onkar Awadhiya, Sunita Aggarwal
Mechanism of Diabetes in pregnancy 217
Diagnosis of GDM 217
Glycemic Targets in GDM 218
Treatment Modalities of GDM 218
Comparison of Insulin versus Metformin in GDM 219
- 38. Early Initiation of Insulin Therapy in Diabetes Mellitus 221**
Rajesh Kumar Jha, Sagar Dembla
Concept and Evolution of Basal Insulin 221
Role of Insulin in Treatment of Type 2 Diabetes Mellitus 222
Benefits of Insulin Therapy in Diabetes Mellitus 222
Barriers to Basal Insulin in Type 2 Diabetes Mellitus 222
How to Start Insulin? 223
- 39. Diabetic Complications in Indian Scenario: An Update 225**
Sidhartha Das, Santosh Kumar Swain, Saroj Kumar Tripathy
Diabetes in India 225
Complications in Type 2 DM 226
Macrovascular Complications 226
Type 2 DM and Metabolic Syndrome 229
Microvascular Complications in Type 2 DM 229
Diabetic Retinopathy 230
Diabetic Neuropathy and Diabetic Foot 230
Other Complications in Type-2 DM 232
- 40. GLP-1 Analogs: Benefits Beyond Glycemic Control 238**
Rajeev Chawla, Shalini Jaggi
GLP-1 Analogs 239
Glycemic Efficacy of GLP-1 Receptor Agonists 241

Extra Glycemic Benefits of GLP-1 Analogs	241
Weight Loss Associated with the Use of GLP-1 Receptor Agonists	242
Side Effects and Associated Risks of GLP-1 Receptor Agonists	243
41. Gliptins versus Sulfonylureas: Which is Better?.....	247
V Palaniappen	
Importance of Glycemic Control in Curbing the Diabetes Burden	247
DM in Elderly Recommendation	259
Negative is not Absolutely Negative in SU Usage	261
Points in Favor of SU	261
42. Metformin—the Molecule of the Decade: Old is Gold.....	262
Sanjay Dash	
History	262
Mechanism of Action	262
Role of Metformin in T2DM	263
Metformin and Body Weight	263
Cancer Biology	264
Adverse Drug Reactions and Contraindications	264
43. A Decade of RCTs in Diabetes: Clinical Implications.....	266
Suhas Erande	
Prelude	266
2007: What Did We Know? DCCT EDIC UKPDS	266
2008: Tighter Glucose Control (?More Benefits)	266
Impact of Recent CVOT in Diabetes on Practice	267
Centrality of RCTS in Clinical Practice	267
Importance of Clinical Practice Guidelines	268
Factors which Influence Physician Practice	268
Have RCTS in Diabetes Helped Clinical Practice in Last Decade?	269
44. Insulin Pumps in India	270
Narendra Pal Jain, Rishu Bhanot	
Insulin Pumps in Type 2 in India	270
Types	271
Indications for an Insulin Pump	271
Current Scenario of Insulin Pumps in India	272

45. Newer Insulins and Art of Insulin Therapy	273
Mangesh Tiwaskar	
Science of Insulin Therapy: The Need	273
Insulins at a Glance	274
Modes of Insulin Delivery	275
Initiating Insulin Therapy	275
Overcoming the Psychological Barriers to Insulin Therapy	277
46. Individualization of Diabetes Care.....	281
KK Pareek, Girish Mathur	
Treatment Approaches for T2 Diabetes	281
Patient–Centered Approach	246
Implementation Strategies	284
Other Considerations	284
Therapeutic Patient Education	285
47. Diabetes and Immunity	286
Apurba Kumar Mukherjee, Indira Maisnam	
Immunity in the Pathogenesis of Diabetes Mellitus	286
Defective Immune Response in Diabetes Mellitus	288
48. Novel Therapeutic Approaches to Preserve Beta Cell Function in Diabetes Mellitus	290
Vijay Negalur	
Pancreatic Beta Cell Mass Function in Diabetes	290
Therapeutic Approaches to Preserve Beta Cell Function in T1D	291
Tumor Necrosis Factor-A (TNF-A) Agonist	293
Therapeutic Approaches to Preserve Beta Cell Function in T2D	293
49. Management of Diabetes in Resource Crunch Countries.....	299
G Prakash	
Prevalence	299
Challenges and the Way Ahead Epidemiological Data	299
Screening	299
Diabetes Management	300
Diabetes Education	300
Pharmacologic Management: Oral Antidiabetic Drugs	300
50. Exercise Prescription for Lifestyle Diseases: A Cornerstone	302
Anil Kumar Virmani	
Lifestyle Diseases	302

- 51. Nonhigh-Density Lipoprotein Cholesterol: Primary Target for Lipid Lowering 305**
 SN Narasingan
 Non-HDL-C as an Indicator of ASCVD Risk 305
 Other Advantages of Non-HDL-C 307

SECTION 4 ENDOCRINOLOGY

- 52. Growth Hormone Replacement Therapy: Current Recommendations..... 313**
 Minal Mohit
 Differences Between COGHD and AOGHD 314
 Consequences of Untreated GHD 314
 Metabolic Complications 314
 Osteopenia/Osteoporosis 314
 Quality of Life 315
 Transitional Care of GHD 315
 Diagnosis of GHD in Adults 315
 Factors Affecting GH Dosing 316
 Dosing Strategies 317
 Safety Issues with GH Replacement Therapy 318
 Unapproved Uses of GH in Adults 319
- 53. Vitamin D Therapy: Hope or Hype..... 326**
 PK Sasidharan
 Vitamin D Basic Facts 326
 Landmark Study on Vitamin D Deficiency 326
 Reasons for Widespread Deficiency of Vitamin D 327
- 54. Approach to a Patient with Short Stature 333**
 Indira Maisnam
 Physiology of Normal Growth 333
 Patterns of Normal Growth 333
 Diagnostic Approach to a Child with Short Stature 334
- 55. Logical Approach to Thyroid Nodule..... 337**
 KJ Shetty, KN Manohar
 Clinical Presentation 337
 Management 338

- 56. Primary Hypoparathyroidism and its Management..... 341**
 Ajay Aggarwal, Roopak Wadhwa
 Epidemiology 341
 Pathophysiology 341
 Signs and Symptoms 342
 Investigations 342
 Treatment 342
- 57. A New Look at Testosterone Therapy in Aging Males 344**
 DC Sharma
 Changes in Reproductive Hormones with Age 344
 Effects of Decrease in Testosterone 344
 Suggested Approach 345
- 58. Lipohypertrophy Secondary to Insulin Injection Therapy 347**
 Sunil Gupta
 Prevalence 347
 Definition of Lipohypertrophy 347
 Causes of Lipohypertrophy 347
 Diagnosis 348
 Clinical Consequences of Lipohypertrophy 348
 Management 350

SECTION 5 NEUROLOGY

- 59. Headache: Headache for Physician..... 355**
 Gurubax Singh
 Every Head has its Own Headache 355
 First Severe Headache 355
 Chronic Daily Headache 356
 Headache in Elderly 357
 Status Migranosus 357
 Menstrual Migraine 357
 Headache with Comorbidities 357
- 60. Approach to Multiple Cranial Nerve Palsy..... 359**
 K Mugundhan
 Intrinsic vs Extrinsic Brainstem Lesions 359

61. Nocturia: Evaluation and Management.....	363
Anish Kumar Gupta	
Clinical Presentation	363
Pathophysiology	363
Treatment	365
Multidisciplinary Management	366
62. Neuromyelitis Optica: A Physician's Perspective.....	367
Mrinal Kanti Roy, Sujoy Sarkar	
Epidemiology	367
63. First Seizure: Should or Should not be Treated?.....	371
PK Maheshwari, A Pandey, Akhilesh Kumar Singh	
Importance of Multiple Seizures	371
Is There any Role of Antiepileptic Drug Prophylaxis?	371
When to Initiate Antiepileptic Drugs?	372
Seizure Recurrence	372
Approach to a Case of First Seizure	373
Management of First Seizure	374
64. An Overview and Practical Clinical Hints in the Diagnosis of Temporal Lobe Epilepsy.....	376
Venkataraman Nagrajan	
Definition	376
Etiology	376
Pathology	376
Pathophysiology	376
Clinical Features	377
International Classification of the CPS	377
Seizure Phenomena	377
Eeg Phenomenon in TLE or CPS	378
Imaging Studies CT vs MRI	378
Differential Diagnosis	378
Management	379
Prognosis	379
65. Changing Scenario in Management of Status Epilepticus.....	380
Rajesh Shankar Iyer	
Changing Definitions and Classification	380
New Terminologies	381

Super-refractory Status Epilepticus 382
 Treatment of Super-refractory SE: An Update 382

66. Present Status of Thrombolysis in Acute Ischemic Stroke: Indian Scenario 386

V Shankar

Rates of Thrombolysis 386
 Thrombolysis Outcomes 386
 Thrombolysis Dosage 387
 Sonothrombolysis 387
 Tenecteplase 387
 Telestroke 387
 Complications and Other Observations 387
 Intraarterial TPA 388
 Thrombolysis and Endovascular Therapy 388

67. Immunomodulation in Neurological Disorders 389

Man Mohan Mehndiratta, Ashish Duggal

Central Nervous System Disorders 389
 Immunotherapy for MS Relapses 389
 Disease-modifying Immunotherapy for MS 392
 Myelin Oligodendrocyte Glycoprotein (MOG) Associated Demyelination 394
 Acute Disseminated Encephalomyelitis 395
 Primary Angiitis of CNS 398
 Disease Affecting the Peripheral Nervous System 398

68. Vertigo: Clinical Approach and Management 404

Lakshmi Narasimhan Ranganathan, Tamil Pavai N,
 Guhan R, Arun Shivaraman MM, Mugundhan Krishnan

Treatment of Vertigo 410

SECTION

6

GASTROENTEROLOGY/HEPATOLOGY

69. Acute Upper Gastrointestinal Bleeding 415

Rajesh Upadhyay, Deepak Sharma

Etiology 415
 Risk Factors 415
 Clinical Presentation 416
 Management 416

Medical Therapy	417
Endoscopic Therapy	417
Surgical Treatment	418
Angiographic Therapy	418
Prevention of Re-bleed	419
70. Acute Pancreatitis	421
G Loganathan, L Santhosh Vivekanadan	
Etiopathogenesis	421
Clinical Features, Diagnosis and Severity Prediction	423
Management	426
Beyond the Early Phase	428
Prevention	432
71. The Gut Microbiota: A Forgotten Organ	436
Balvir Singh, Ram Prakash Pandey, Mridul Chaturvedi, TP Singh, Ashish Gautam	
Composition of Gut Microbiota	436
Humans as Microbial Depots	436
Emergence of Microbiota	436
Gut Microbiota as an Organ	437
Link Between Gut Flora and Diseases	438
Future Hopes for Various Diseases	438
72. Nonalcoholic Fatty Liver Disease: Is it Really Benign?.....	442
AK Chauhan	
NAFLD is a Progressive Condition	442
Role of Metabolic Risk Factors in Disease Progression	443
Pathophysiologic Link of Metabolic Risk Factors with HCC	443
Extrahepatic Complications of Nafld	444
73. Glucose Metabolism Disorders in Chronic Liver Disease.....	446
Aparna Agrawal, Prashasti Gupta	
Role of Liver in Carbohydrate Metabolism	446
Glucose Metabolism in Diseased Liver	446
Mechanism of IR and GMD in CLD	446
Mechanism of LD in DM	447
Burden of GMD and IR in CLD and of LD in DM	447
Correlation of GMD with Etiology and Severity of CLD and Risk Factors of DM	447
Clinical Presentation of GMD in CLD	447

Implications of GMD on Complications of CLD 448

Diagnosis and Monitoring 448

Treatment of GMD in CLD 448

Results of Our Study 449

74. Hepatorenal Syndrome: Clinical Considerations 451

Tanuja Pravin Manohar

Definition 451

Epidemiology 451

Pathophysiology 451

Precipitating Factors 452

Diagnosis 453

Diagnostic Criteria for Hepatorenal Syndrome 453

Preventive Measures 453

Biomarkers in HRS 453

Treatment 453

75. Cirrhosis of Liver: Beyond Beta-blockers and Diuretics 456

Anup K Das

Variceal Hemorrhage 456

Hepatorenal Syndrome (HRS) 457

Spontaneous Bacterial Peritonitis (SBP) 457

76. Hepatitis B: Are We Moving Ahead Towards Cure? 463

Anil C Anand

Epidemiology of HBV in India 463

The Virus 464

Immunopathogenesis 464

Natural History of HBV Infection 464

Management of Chronic HBV Infection and Innovative Approaches 465

Newer Drugs and Innovative Approaches 465

77. HIV/Hepatitis Coinfections 469

PK Agrawal

Epidemiology 469

Pathogenesis 469

Treatment 470

78. Fecal Microbiota Transplantation: Current Indications and Methods.....	472
L Ilavarasi, SS Lakshmanan	
Fecal Microbiota Transplantation Techniques	472
Donor Selection	472
History to be Obtained from the Donor	474
Stool Evaluation	474
Donor Blood Screening	474
Donor Stool Preparation: European Consensus 2017	474
Routes of Administration of FMT	474
Colonoscopy Guided	474
Upper GI Endoscopy Guidance	474
<i>Clostridium Difficile</i> Infections	474
Inflammatory Bowel Disease	475
Irritable Bowel Syndrome	475
FMT in Obesity/Insulin Resistance and Diabetes	475
FMT in Neurological Diseases	475
Current and Future Directions	475

SECTION 7 RESPIRATORY SYSTEM

79. Clinical Approach to a Patient of Dyspnea	481
Alok Gupta, Rajat Gupta	
Mechanism	481
Causes of Dyspnea	482
Assessment Of Dyspnea	487
History Taking	489
Physical Examination	489
Laboratory Studies	490
Advanced Studies	491
Management	493
80. Syndrome Z	495
Devendra Prasad Singh	
OSA and Hypertension	495
Obesity	495

Insulin Resistance	495
Pathophysiology of Syndrome Z	495
Diagnosis of Syndrome Z	497
OSA: Clinical Features	497
OSAs and Hypertension	497
Lifestyle Modifications	498

81. Asthma COPD Overlap Syndrome..... 500

Kashinath Padhiary

Definition	500
Incidence	500
Pathogenesis	501
Contributing Factors	501
Clinical Features	501
Diagnosis	501
Prognosis	502
Treatment	502

82. Global Warming and its Health Impact..... 504

PS Shankar

Health Impact	504
Surface Temperature	504
El Nino	505
Ozone	505
Diseases	505
Future	506

83. ARDS: Recognition and Management..... 508

Niteen D Karnik, Priya Bhate

Recognition	508
Diagnosis	508
Management	508

84. Clinical Approach to Solitary Pulmonary Nodule 514

BNBM Prasad

Definition	514
Causes	514
Prevalence	515
Approach to Diagnosis	515
Management	521

85. Challenges in the Management of CAP	525
Prashant Prakash, Akhilesh Kumar Singh	
Definition of CAP	525
Epidemiology and Etiology	525
Diagnosis of CAP	525
Role of Microbiological Investigations in CAP	526
General Investigations and Risk Stratification Required in Patients with CAP	528
Antimicrobial Therapy in CAP	529
86. Air Pollution and its Health Impact.....	533
Vishal Chopra, Prabhleen Kaur, Siddharth Chopra	
Mechanisms Leading to Health Effects	533
Types of Pollutants	534
Effects of Air Pollution on Different Organs	534

SECTION 8 INFECTIONS

87. Infections Causing Cancer	539
Anupam Dey	
Pathogenesis	539
International Agency for Research on Cancer (WHO) Classification	539
Mechanisms by which Common Agents Cause Cancers	540
Detection and Proving Association of the Infectious Agent in Cancer	540
88. Transfusion Transmitted Infection	543
Apu Adhikary, Tuhin Santra	
Human Immunodeficiency Virus	543
Hepatitis B virus	544
Hepatitis C virus	544
Malaria	544
Syphilis	544
Human T-Lymphotropic Virus I and II	544
Cytomegalovirus	545
Epstein–Barr virus	545
West Nile Virus	545
Parvovirus B19	545
Arboviruses	545
Bacterial infections	545

Other Infectious Agents 546
Pathogen Inactivation Technology 546
Donor Screening Questionnaire 546

89. Arboviral Infections: Is Effective Vaccination a Possible Solution? 547

Ashok Kumar, Shubha Laxmi Margekar, Venugopal Margekar

Transmission 547
Clinical Findings and Epidemiology 548
Vaccination 548
Yellow Fever Vaccine 549
Japanese Encephalitis 549
Dengue Vaccine 550
Chikungunya Vaccine 551
Kyasanur Forest Disease 551
Crimean Congo Hemorrhagic Fever Virus 552

90. MDR-TB and XDR-TB: What are the Options? 553

Bidita Khandelwal

Epidemiology 553
Defining MDR-, Pre-XDR- and XDR-TB 553
Management Options in M/XDR-TB 553
Regimes 554
Newer Drugs Options 554
High-Dose Isoniazid 555
Duration of Treatment M/XDR-TB 555
Surgical Options 555

91. Acute Encephalitis: Indian Scenario 556

Debasis Chakrabarti, Shankha S Sen

Etiology 556
Epidemiology 556

92. Tropical Fever: A Case-based Approach..... 562

Manoranjan Behera, Sidhartha Das, Jayant Kumar Panda

Specific Infections 564
Investigation Strategy 566
Treatment Strategy 566

93. Vivax Malaria: No Longer Benign!	570
K Nagesh	
Epidemiology	570
Malaria Parasite	571
Vivax Malaria	571
Malignant Behavior of <i>Plasmodium Vivax</i>	572
Pathophysiology	573
Clinical Features	573
Clinical Classifications	573
Management	574
Treatment of Malaria in Pregnancy	574
Clinical Malaria	575
94. Newer Modalities in Diagnosis of Tuberculosis	576
Prem Parkash Gupta	
Direct Sputum Smear Microscopic Examination	576
Culture-Based Methods for the Diagnosis of Tuberculosis	576
Rapid Detection of Drug Resistance: In-house Methods	577
Colorimetric Redox Indicator Methods	578
Diagnosis of TB Based on DNA Tools	578
Latent Tuberculous Infection Diagnosis	580
95. Resurgence of Yellow Fever: A Great Challenge	583
Rajib Ratna Chaudhary	
Transmission of Yellow Fever Virus	583
Pathogenesis	584
Clinical Presentation	584
Laboratory Finding	584
Differential Diagnosis	585
Treatment and Prevention	585
Prognosis	585
96. Complicated Dengue	586
Rajeev Gupta	
Introduction to Dengue	586
Hepatic Complications	587

97. Scrub Typhus: Need for Alert	588
Raman Sharma, Sunil Mahavar, Mayank Gupta	
Etiology	588
Epidemiology and Transmission	588
Clinical Manifestations	589
Diagnosis	590
Differential Diagnosis	590
Treatment	590
Prevention	591
98. Pyrexia of Unknown Origin: Current Concept	592
SV Ramana Murty, Chakravarthy DJK	
Epidemiology	592
99. Approach to a Patient of Meningitis.....	600
Sanjiv Maheshwari, Vijay Prakash Hawa	
Clinical Presentation	600
Examination	601
Investigation	602
CSF Examination	602
Other Laboratory Studies	603
Neuroimaging	603
Treatment	603
100. Leptospirosis: What We Should Know?	604
Shantanu Kumar Kar, Paluru Vijayachari, Jayant Kumar Panda	
Epidemiology	604
Clinical Presentation	605
Diagnosis	605
Treatment and Prevention	606
101. Kala-azar Elimination in India	607
Shyam Sundar	
102. Sickle Cell Crisis: How to go Forward?	610
Srikant Kumar Dhar	
How to Diagnose?	610
How to Manage?	610
Principles of Management	611
Analgesia	611

Fluid Replacement	611
Treatment of Acute Chest Syndrome	611
Recommendations for Vaccination	613
103. Do Not Rash When Fever Coincides with Rash	614
Sriprasad Mohanty	
Approach to Diagnosis	614
Viral hemorrhagic Fevers	615
104. Disseminated Intravascular Coagulation: Management Updates.....	617
Puneet Saxena, Aradhna Sharma, Madhulata Agarwal, Sher Singh Dariya, Hitesh Sharma	
Pathogenesis	617
Diagnosis	618
Differential Diagnosis	619
Treatment	620
105. Adult Immunization: Current Scenario in India.....	622
Prasanta Kumar Bhattacharya, Subrahmanya Murti V	
Hepatitis B Vaccine	622
Hepatitis A Vaccine	624
Diphtheria, Pertussis and Tetanus Vaccines	624
Measles, Mumps and Rubella Vaccine	624
Varicella and Zoster (Shingles) Vaccines	624
Pneumococcal Vaccine	625
Meningococcal Vaccine	625
Haemophilus Influenzae Vaccine	626
Human Papilloma Virus Vaccine	626
Influenza Vaccine	626
Japanese Encephalitis Vaccine	626
Yellow Fever Vaccine	626
Cholera Vaccine	626
Typhoid Vaccine	626
Newer Vaccines	627
106. H1N1 Influenza: 9 Years' Journey in Gujarat.....	629
Asha N Shah	
History of Reassortment Events in the Evolution of the 2009 Influenza A (H1N1) Virus	629
Government of India Guidelines on Categorization of Seasonal Influenza A H1N1 Cases (Revised on 11-2-2015)	630
Cytokine Storm in Young	632

107. Ebola	636
Rajeev Raina, Nidhi Raina	
Background	636
Transmission	636
Clinical Symptoms	638
Diagnosis	639
Treatment and Vaccines	639
Lessons Learnt	639

SECTION 9 HUMAN IMMUNODEFICIENCY VIRUS

108. 90-90-90 Strategy in HIV Epidemic	645
R Sajith Kumar	
Treatment Target	645
Reaching Target 1	648
Reaching Target 2	648
Reaching Target 3	649
Ending the AIDS Epidemic	650
109. ART in HIV Infection: State-of-the-Art.....	652
BB Rewari, Manish Bamrotiya, Suman Singh	
Antiretroviral Therapy for HIV Infection	652
Goals of Antiretroviral Therapy	652
Clinical Pharmacology of Commonly used ARV Drugs	653
Considerations before Initiation of ART	654
Recommended Choice of First Line Regimen	656
Monitoring of Patients on ART	656
Treatment Failure: When to Change and What to Change	658
110. Opportunistic Infections in HIV: Changing Scenario.....	660
Amar R Pazare	
Common Opportunistic Infections in HIV-infected Patients in the Past	660
111. Neurological Manifestations of HIV.....	663
Dipanjan Bandyopadhyay, Amit Adhikary	
Acute Seroconversion Illness	663
Direct Viral Invasion	663
Myelopathy due to HIV	663

Peripheral Neuropathy	664
Opportunistic Infections Affecting the CNS	664
Progressive Multifocal Leukoencephalopathy	666
HIV Associated Malignancies Affecting the CNS	666
Neurological Disease Arising from ART	666
112. Cardiopulmonary Manifestations of HIV	667
Alaka K Deshpande	
Pericardial Disease	667
Cardiotoxic Drugs	668
Coronary Artery Disease	668
Pulmonary Manifestations	669
Bacterial Infections	669
Fungal Infections	670
Malignant Neoplasms	670
113. Immune Reconstitution Inflammatory Syndrome	671
Vinay Rampal	
Background	671
Definition	671
Clinical Factors Associated with the Development of IRIS	672
Mycobacterium Tuberculosis IRIS	673
Atypical Mycobacterial IRIS	674
Cytomegalovirus Infection IRIS	674
Varicella Zoster Virus Infection IRIS	675
Cryptococcus Neoformans Infection IRIS	675
Other Etiologies	676

SECTION 10 INTENSIVE CARE UNIT

114. Critical Care Toxicology: Update 2018	681
Omender Singh, Deven Juneja	
Initial Resuscitation and Management	681
Laboratory Investigations	682
Decontamination	682
Enhanced Elimination	682

- 115. Hypoglycemia in ICU 684**
Sundaram Arulraj, Aarathy Kannan, Manikandan R, Vinodh Kumar A
Classification of Hypoglycemia 684
Pathogenesis of Hypoglycemia in ICU 684
Acute Coronary Syndrome 690
- 116. Biomarkers in Sepsis 695**
Virendra Kumar Goyal, Mohit Goyal
C-reactive Protein 697
Biomarker Combinations 698
Statement of UNMET Need 698
- 117. Early and Empiric Antibiotics in Sepsis: Current Controversy 700**
Trupti H Trivedi
Future Therapy 703
- 118. Arterial Blood Gas Analysis: Simple Steps for Understanding 705**
Ravindra Kumar Das
Collection of Blood Samples and Transportation 705
Method of Analysis 705
Case History/Provisional Diagnosis 710
- 119. Superbugs in ICU and the Need for Antibiotic Stewardship 716**
Pankaj Kumar
- 120. Perioperative Management in Diabetes 720**
Pramod Kumar Sinha
Risks of Poor Diabetic Control 720
Factors Causing Adverse Outcome 720
Metabolic Response to Surgery and Anesthesia and the Effect of Diabetes 721
Principles and Target of Perioperative Management 721
Preoperative Measures 721
Intraoperative Management 722
Measures During Surgery 722
Postoperative Management 724
- 121. Hospital Acquired Infections 725**
Piyush Jain
Nosocomial Pneumonia 725
Diagnosis 726

Causative Organisms	726
Treatment	726
Preventive Measures	727
Nosocomial Urinary Tract Infections	727
Diagnosis	727
Treatment	727
Catheter Related Blood Stream Infection	728
Diagnosis	728
Treatment	728
Nosocomial Surgical Site and Soft Tissue Infection	728
Management	729

SECTION 11 TOXICOLOGY

122. Clinical Approach to Patient of Coma.....	733
Geeta Kampani, Umashankar US, Munish Prabhakar	
Etiology and Pathogenesis	733
Assessment of COMA	733
History	733
General Physical Examination	733
Neurologic Examination	734
Brainstem Reflexes	735
Respiratory Patterns	735
Investigations	735
Prognosis	736
123. Common Poisoning and Management.....	737
Saurabh Srivastava	
Aluminium Phosphide Poisoning (Celphos Poisoning)	737
Mechanism of Toxicity	737
Clinical Features of Intoxication	737
Organophosphate Poisoning	738
Mechanism of Toxicity	738
Clinical Features	738
Management	739
Corrosive Poisoning	739
Mechanism of Injury	739

Clinical Presentation	739
Management	740
Rodenticides	740
Zinc Phosphide	740
Anticoagulants	740
Kerosene Oil	740
Clinical Features of Intoxication	740
Management	740
Benzodiazepines	740
Clinical Features of Intoxication	740
Management	741
124. Management of Snake Bite in India.....	742
Shibendu Ghosh, Prabuddha Mukhopadhyay	
Snake Bite Prevention and Occupational Risk	744
Preventative Measures	744
Diagnosis Phase	744
General Signs and Symptoms of Viperine Envenomation	744
Late-onset Envenoming	747
Diagnosis Phase: Investigations	747
Management of Snake Bite in General	747
Handling Tourniquets	748
ASV Administration Criteria	748
Prevention of ASV Reactions: Prophylactic Regimes	749
Neurotoxic Envenomation	751
Recovery Phase	751
AntiHemostatic Maximum ASV Dosage Guidance	752

SECTION 12 HEMATOLOGY/ONCOLOGY

125. Stem Cell Therapy in Various Diseases: Dawn of a New Era	759
Sunita Aggarwal, Jahnvi Dhar, Sandeep Garg	
Stem Cell	759
Methods for Stem Cells Transplantation	759
Hematopoietic Stem Cell Transplantation (HSCT)	759
Scope of Stem Cell Therapy in India	761

- 126. Basics of Hematopoietic Stem Cell Transplant: Autologous and Allogeneic..... 763**
Punit L Jain
Principles of HSCT 763
- 127. Clinical Approach to Patient with Purpuric Spot..... 767**
Chanchal Kumar Jana, Gaurab Bhaduri
Pathophysiology 767
Causes of Nonpalpable Purpura 767
Causes of Palpable Purpura 768
Clinical Approach to Purpuric Spots 768
Case Studies 768
Diagnosis: Henoch–Schönlein Purpura 768
Diagnosis: Purpura Fulminans 769
Management of Some Common Causes of Purpura 769
- 128. Thrombocytosis: Clinical Approach..... 772**
Sudhir Mehta, Laxmi Kant Goyal, Shaurya Mehta, Gunja Jain
Regulation of Thrombopoiesis 772
Causes of Thrombocytosis 773
Clinical Features 775
Differential Diagnosis 775
Treatment 776
- 129. Macrophage Activation Syndrome..... 778**
Tarun Kumar Dutta, Tony Kadavanu, Arunkumar Ramachandrapa
Epidemiology 778
Etiopathogenesis and Triggers 778
Clinical Features 778
Laboratory Features 779
Diagnostic Criteria 781
Further Approach 781
Differential Diagnosis 781
Management 781
Biologicals 782
- 130. Hemotransfusion Therapy: Boon or Bane?..... 784**
Anil Kumar Gupta
Hemotherapy: A Precious Tool for Humans 784
Hemotherapy, Inherent Risks 785

131. Idiopathic CD4 Lymphocytopenia	788
Bhupendra Gupta, Harpreet Singh	
Pathogenesis	788
Clinical Manifestations	788
Infections	788
Evaluation	789
Diagnosis	789
Treatment	790
Other Treatment Modalities	790
Prognosis	790
132. Hepatocellular Carcinoma: Surveillance, Diagnosis and Management.....	791
Kirti Shetty	
Background	791
Surveillance Strategy	791
Target Population	791
Tests	791
Diagnosis	792
Tissue Diagnosis	792
Staging	792
Treatment	792
Surgical Therapies for HCC	793
133. Approach to a Patient with Polycythemia	795
Mathew Thomas	
Introduction, Definitions and Classification	795
Mechanisms	795
Major Causes of Polycythemia	796
Initial Evaluation of Patients with Polycythemia	796
Physical Examination	797
Systemic Examination	797
Laboratory Investigations	797
Further Diagnostic Approach	797
Further Evaluation	797
Diagnosis of Polycythemia Vera	798
Treatment of Polycythemia Vera	798
Management of Secondary Polycythemia	800

- 134. Immunotherapy: A New Weapon in Cancer Treatment 801**
 Vineet Talwar, Venkata Pradeep Babu K
 Oncolytic Viruses in Immunotherapy 801
 Vaccines in Immunotherapy 802
 Adoptive Cell Therapy 802
 Immune Check Point Blockade 802
- 135. Metronomic Chemotherapy in Metastatic Malignancies: A New Concept 805**
 Ankur Bahl
 Metronomic Chemotherapy Versus Conventional Chemotherapy 805
 Angiogenesis–Chemotherapy Model 806
 Activation of Immunity 806
 Rational of Various Drugs Used in Metronomic Chemotherapy 806
 Metronomic Chemotherapy in Adult Cancers 807
 Toxicity of Metronomic Chemotherapy 807

SECTION 13 RHEUMATOLOGY

- 136. Asymptomatic Hyperuricemia: What to Do?..... 811**
 Arup Kumar Kundu, Shyamashis Das
 Epidemiology 811
 Definitions 811
 Why Hyperuricemia Occurs? 811
 Clinical Consequences of Persistent Hyperuricemia 812
 Evaluation of Patients with Asymptomatic Hyperuricemia 813
 When to Treat Asymptomatic Hyperuricemia? 813
- 137. Polyarteritis Nodosa: An Enigma..... 815**
 Ghan Shyam Pangtey, Paramjeet Singh
 Case Vignette 815
 Introduction 816
 Epidemiology 817
 Clinical Features 817
 Laboratory Evaluation and Imaging 818
 Prognosis 818
 Management 819

- 138. Chikungunya Arthritis..... 821**
Harpreet Singh, Neeraj Kumar
- 139. Clinical Approach to a Patient with Vasculitis..... 825**
N Subramanian
Pathogenesis 825
Classification 825
Clinical Features 825
Investigations 827
Management 827
Practical Points 828
- 140. Osteoporosis Screening, Prevention, and Treatment..... 830**
Tanu Shweta Pandey
Osteopenia 830

SECTION 14 NEPHROLOGY

- 141. Recipient and Donor Selection for Renal Transplantation in India: Current Status 837**
Sanjay Kumar Agarwal
Advantages of Renal Transplant over Maintenance Dialysis 837
Contraindication of Renal Transplantation 837
Recipient Evaluation 837
Donor Evaluation 839
- 142. Rituximab: Panacea of Glomerular Diseases..... 842**
Dipankar M Bhowmik, N Rajkanna
Primary Glomerular Diseases 843
Glomerular Diseases that Cause Nephrotic Syndrome: Immune Complex 843
Secondary Glomerular Diseases 844
Adverse Effects of Rituximab 844
- 143. ABO-Incompatible Kidney Transplantation 846**
Dinesh Khullar, Sagar Gupta
Historical Perspective 846
ABO Antigens and Blood Groups 847
Pathogenesis 847
Accommodation 847

Techniques of Desensitization 847

Complications 848

144. Prevention and Management of Diabetic Kidney Disease..... 849

Pritam Gupta, Rajesh Aggarwal, Blessy Sehgal

Spectrum of Renal Involvement in Diabetes Mellitus (Type 2) 849

Risk Factors for the Development of Diabetic Nephropathy 849

Management of Microalbuminuria in Diabetes 851

Screening for Diabetic Kidney Disease 851

Other Biochemical Markers 851

Natural History of Type I Diabetic Nephropathy 851

Treatment Target 851

What is Optimal Target HBA_{1c}? 852

Blood Pressure Control 852

Blockade of Renin Angiotensin System 852

Treatment of Dyslipidemia in Diabetic Nephropathy 853

Emerging and Future Therapies 853

145. Anemia in Chronic Kidney Disease: Management..... 854

HK Aggarwal, Deepak Jain, Rahul Chauda

Anemia in Chronic Kidney Disease: Management 854

Diagnosis and Evaluation 854

Treatment 854

Erythropoiesis Stimulating Agents 855

Blood Transfusion 856

Other Therapies 856

Option in Future 857

SECTION 15 GERIATRICS AND GENETIC

146. Geriatric Teaching Indian Relevance 861

OP Sharma

Ageing 861

Medical Infrastructure 862

Geriatrics Services 862

Need v/s Availability 863

Need Based Solutions 863

- 147. Therapeutic Uses of Human Endothelial Progenitor Cells 865**
 Ananda Bagchi, Aradhya Sekhar Bagchi
 Isolation of EPC 866
 Therapeutic Uses of EPC 866
 EPCs and Cardiovascular Risk factors 866
 EPC and Atherosclerotic Cardiovascular Disease 867
 EPCs and Cardiovascular Trials 868
 Effect of Cardiac Drugs on EPCs 868
 ACE Inhibitors and Angiotensin II Receptor Blockers 868
 CD34 Antibody Coated Stents 868
 Uses of EPCs in Diabetes Mellitus 869
 Role of EPCs in Tumor Growth 869
 Role EPCs in Endometriosis 869
 Uses of EPCs in Wound Healing 869
 Uses of EPCs in Peripheral Arterial Obstructive Disease 870
- 148. Management of Gender Dysphoric Persons, Sex Change Surgeries
 and Our (Indian) Experience 872**
 Richie Gupta, Rajat Gupta
- 149. Anemia in Elderly: Experience at a Large Tertiary Center..... 876**
 PS Ghalaut, Ragini Ghalaut
 Classification of Anemia 876
 Diagnosis of a Case with Anemia in Elderly 878
 Investigations in Anemia in Elderly 878
 Management of Anemia in Elderly 880
 Indications of Blood Transfusion 881

SECTION 16 SOCIAL ISSUES

- 150. Medical Ethics 885**
 Hem Shanker Sharma
 Theories of Medical Ethics 885
 Governing Bodies and Rules 887

151. Soul and Spiritual Health	888
SP Yoganna	
Origin and Evolution of Universe—Matter and Energy theory (Big Bang Theory)	888
Natural Principles of Universe	888
Human is a Manifestation of Universal Energy	889
Human Being is the Miniature of the Universe	889
Human Being is Holistic	889
PreProgrammed Evolution and Human Body Functions	890
Life Energies	894
Soul (Atma)	895
Ways of Acquiring Spiritual Energy	897
God and God Men	898
What is Spiritual Health?	899
Diagnostic Approach	899
152. Cooking Oils: Which to Use?	901
Sonia Arora, Vitull K Gupta, Meghna Gupta	
Composition of Fats	901
Trans Fatty Acids or Partially Hydrogenated Fatty Acids	902
What are Cooking Oils?	903
Choosing the Right Oil	904
Why Blends are Needed?	905
153. IT Solution in Regulation of Medical Education and Medical Practice.....	906
Ajay Kumar	

SECTION 17 MISCELLANEOUS

154. Changing Trends in Medicine: Past, Present and Future	909
Pritam Gupta, Ghan Shyam Pangtey, Sujata Mangla	
Medicine Before the 20th Century	909
Medicine in the 20th Century	911
Medical Science and Technology in 21st Century	913
Future Medical Inventions	915

- 155. Isoniazid Preventive Therapy: Operational Guidelines..... 918**
Mohanjeet Kaur, Ashish Chawla
TB and HIV 918
HIV-TB Collaborative Activities 918
Single Window Services 918
Isoniazid Preventive Therapy 919
Why INH for IPT? 920
Evaluation of the Patients (Before Starting IPT) 920
Regimen Plan for IPT 920
Concomitant Use of IPT with ART 920
Can Co-Trimoxazole be Dispensed with IPT? 920
Drug Resistance with IPT 921
- 156. Hypnotherapy in Medical Disorders..... 922**
Rajeev Mohan Kaushik
Areas of the Brain Affected by Hypnosis 922
Physiological Effects of Hypnosis 923
Factors Affecting Therapeutic Response 923
Types of Hypnosis 923
Applications of Hypnotherapy in Medical Disorders 924
Hypnoanalysis 925
Prospects 925
- 157. An Approach to Recurrent Falls in the Elderly 926**
S Ramnathan Iyer, Revati R Iyer
- 158. Ultrasonography in Critically Ill Patients 929**
Sameer Gulati, Bhupendra Gupta
Equipment 929
Procedure: Lung Ultrasonography 929
Procedure: Compression Ultrasonography for Deep Vein Thrombosis 931
Procedure: Bedside Ocular Ultrasound 931
Procedure: Focussed Echocardiography 932
Procedure: Screening Abdominal Ultrasonography 933
Ultrasonography in Trauma 933
Advantages and Limitations 934

159. Imaging Parameters in Pulmonary Thromboembolism	935
Priya Jagia, Niraj Nirmal Pandey	
Diagnosis of Pulmonary Embolism and Deep Venous Thrombosis	935
Imaging Modalities	935
Assessment of Pulmonary Embolism Severity and Prognostication	937
Diagnostic Algorithm in a Patient of Suspected PE	939
 <i>Index</i>	 941